Unique Ingredient Identifier 8MDF5V39QO is listed as a ingredient substance
| RN | 144-55-8 |
| EC | 205-633-8 |
| NCIT | C29457 |
| RXCUI | 36676 |
| PUBCHEM | 516892 |
| MF | CHO3.Na |
| INCHI KEY | UIIMBOGNXHQVGW-UHFFFAOYSA-M |
| SMILES | [Na+].OC([O-])=O |
UNII 8MDF5V39QO SODIUM BICARBONATE is commonly included in medications in the following forms.
| Route | Dosage Form | Potency |
|---|---|---|
| BUCCAL | GUM | 7.2 MG |
| BUCCAL | GUM, CHEWING | 25 MG |
| BUCCAL | TABLET | 42 MG |
| IM - IV | INJECTION | 175 MG/VIAL |
| IM - IV | INJECTION | NA |
| IM - IV | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | ADJPH |
| IM - IV | POWDER, FOR RECONSTITUTION | ADJPH |
| INTRAMUSCULAR | INJECTABLE | 175 mg/1VIAL |
| INTRAMUSCULAR | INJECTION | 3.5 % |
| INTRAMUSCULAR | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRAPERITONEAL | POWDER, FOR INJECTION SOLUTION | ADJPH |
| INTRATHECAL | INJECTABLE | NA |
| INTRATHECAL | INJECTION | 0.005 % |
| INTRATRACHEAL | SUSPENSION | ADJPH |
| INTRAVENOUS | INJECTABLE | 175 mg/1VIAL |
| INTRAVENOUS | INJECTION | 764.66 mg/1VIAL |
| INTRAVENOUS | INJECTION | ADJPH |
| INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 573.5 mg/1VIAL |
| INTRAVENOUS | POWDER, FOR INJECTION SOLUTION | 2.1 % |
| INTRAVENOUS | SOLUTION, INJECTION | ADJPH |
| INTRAVITREAL | INJECTION | 0.18 % |
| IV(INFUSION) | INJECTION | 3.5 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION | 6 % |
| IV(INFUSION) | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | 0.18 % |
| ORAL | CAPSULE | 108 MG |
| ORAL | CAPSULE, DELAYED ACTION | 0.36 MG |
| ORAL | CAPSULE, HARD GELATIN | 2 MG |
| ORAL | FILM, SOLUBLE | 0.6 MG |
| ORAL | GRANULE, EFFERVESCENT | NA |
| ORAL | GUM, CHEWING | 15 MG |
| ORAL | POWDER, FOR SOLUTION | 87.2 MG/1GM |
| ORAL | POWDER, FOR SUSPENSION | NA |
| ORAL | SOLUTION | NA |
| ORAL | SUSPENSION | 5 MG/5ML |
| ORAL | TABLET | 125 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), FILM COATED | 4.24 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE | 140 MG |
| ORAL | TABLET (IMMED./COMP. RELEASE), UNCOATED, EFFERVESC | 267 MG |
| ORAL | TABLET, COATED | 9 MG |
| ORAL | TABLET, DELAYED ACTION, ENTERIC COATED | 30 MG |
| ORAL | TABLET, DELAYED RELEASE | 0.43 MG |
| ORAL | TABLET, EFFERVESCENT, FOR SOLUTION | 1600 MG |
| ORAL | TABLET, EXTENDED RELEASE | 40.4 MG |
| ORAL | TABLET, FILM COATED | 40 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING | 30 MG |
| ORAL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | 1 mg |
| ORAL | TABLET, SUSTAINED ACTION | 2.56 MG |
| ORAL | TABLET, SUSTAINED ACTION, COATED | 2.56 MG |
| SUBCUTANEOUS | INJECTION | ADJPH |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION | 0.016 % |
| SUBCUTANEOUS | POWDER, FOR INJECTION SOLUTION, LYOPHILIZED | NA |
| SUBLINGUAL | TABLET | 3.25 MG |
| TRANSDERMAL | PATCH, ELECTRICALLY CONTROLLED | 10 MG |
| VAGINAL | INSERT | 43 MG |
| VAGINAL | TABLET | 43 MG |